CO6150153A2 - Farmaco de compuesto de cinamida - Google Patents
Farmaco de compuesto de cinamidaInfo
- Publication number
- CO6150153A2 CO6150153A2 CO09000699A CO09000699A CO6150153A2 CO 6150153 A2 CO6150153 A2 CO 6150153A2 CO 09000699 A CO09000699 A CO 09000699A CO 09000699 A CO09000699 A CO 09000699A CO 6150153 A2 CO6150153 A2 CO 6150153A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- substituted
- members
- formula
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 150000001450 anions Chemical class 0.000 abstract 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Seasonings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Cultivation Of Plants (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Un compuesto representado por la Fórmula (I) o su sal farmacológicamente aceptable:Fórmula Icaracterizado porqueRa y Rb son iguales o diferentes y cada uno significa un 1 átomo de hidrógeno o un grupo alquilo C1-6; Xa significa un grupo metoxi o un átomo de flúor; Y significa -CO-(O)nRc.Ma-, en donde Rc significa un grupo alquilo C1-6, grupo de anillo hidrocarburo aromático de 6 hasta 14 miembros, grupo heterocíclico aromático de 5 hasta 14 miembros, grupo de anillo hidrocarburo no aromático de 6 hasta 14 miembros, o grupo heterocíclico no aromático de 5 hasta 14 miembros, que puede substituirse con los mismos o diferentes 1 hasta 5 substituyentes seleccionados del Grupo Substituyente A1; n es 0 ó 1; y Ma- significa un anión, -P(=O) (ORd)2Ma-, en donde Rd significa un grupo alquilo C1-6 que puede substituirse con los mismos o diferentes 1 hasta 3 substituyentes seleccionados del Grupo Substituyente A2, y Ma- significa un anión, -P(=O) (OH)2.Ma-, en donde Ma- significa un anión -P(=O) (-O-) (-O-.Mb+), en donde Mb+ significa un catión; A se representa por la Fórmula (A-1): Fórmula 2]en donde (a) R1, R2, R3, y R4 son iguales o diferentes y cada uno significa un átomo de hidrógeno o un grupo alquilo C1-6, X1 significa un grupo alquileno C1-6 que puede substituirse con 1 hasta 3 grupos hidroxi o alquilo C1-6 que pueden substituirse con 1 hasta 3 grupos hidroxi, X2 significa un átomo de oxígeno o un grupo metileno que puede substituirse con 1 ó 2 grupos alquilo C1-6, y Ar1 significa -X1-a-Ar1-a, en donde Ar1-a significa un anillo hidrocarburo aromático de 6 hasta 14 miembros o ...
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82076106P | 2006-07-28 | 2006-07-28 | |
JP2006206007 | 2006-07-28 | ||
US86925906P | 2006-12-08 | 2006-12-08 | |
JP2006331274 | 2006-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150153A2 true CO6150153A2 (es) | 2010-04-20 |
Family
ID=38981524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09000699A CO6150153A2 (es) | 2006-07-28 | 2009-01-06 | Farmaco de compuesto de cinamida |
Country Status (25)
Country | Link |
---|---|
US (1) | US7737141B2 (es) |
EP (1) | EP2048143A4 (es) |
JP (1) | JPWO2008013213A1 (es) |
KR (1) | KR20090033910A (es) |
AR (1) | AR062095A1 (es) |
AU (1) | AU2007277729A1 (es) |
CA (1) | CA2658037A1 (es) |
CO (1) | CO6150153A2 (es) |
CR (1) | CR10499A (es) |
EA (1) | EA200970172A1 (es) |
EC (1) | ECSP099091A (es) |
GE (1) | GEP20115176B (es) |
HN (1) | HN2009000157A (es) |
IL (1) | IL196351A0 (es) |
MA (1) | MA30636B1 (es) |
MX (1) | MX2008015504A (es) |
MY (1) | MY144971A (es) |
NO (1) | NO20090541L (es) |
NZ (1) | NZ574102A (es) |
PE (1) | PE20080281A1 (es) |
SA (1) | SA07280403B1 (es) |
SV (1) | SV2009003157A (es) |
TN (1) | TN2009000024A1 (es) |
TW (1) | TW200821319A (es) |
WO (1) | WO2008013213A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0511504A (pt) * | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
KR20070083781A (ko) * | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
JPWO2007058304A1 (ja) * | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
CA2628047A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamide derivative |
TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
WO2007060810A1 (ja) * | 2005-11-24 | 2007-05-31 | Eisai R & D Management Co., Ltd. | モルホリンタイプ・シンナミド化合物 |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
CL2008000582A1 (es) * | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
KR20100016580A (ko) * | 2007-05-16 | 2010-02-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 유도체의 원폿 제조 방법 |
US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
CA2694401C (en) | 2007-08-31 | 2012-12-04 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
EP2234954B1 (en) | 2007-12-20 | 2015-02-18 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
EP2234999A1 (en) | 2007-12-21 | 2010-10-06 | F. Hoffmann-La Roche AG | Heteroaryl derivatives as orexin receptor antagonists |
US7923450B2 (en) | 2008-01-11 | 2011-04-12 | Hoffmann-La Roche Inc. | Modulators for amyloid beta |
CA2712095A1 (en) * | 2008-01-28 | 2009-08-06 | Eisai R&D Management Co., Ltd. | Crystalline cinnamide compounds or salts thereof |
AU2009216851B2 (en) | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
WO2010052199A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
ES2711619T3 (es) * | 2010-07-02 | 2019-05-06 | Bio Pharm Solutions Co Ltd | Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto |
US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
KR101551041B1 (ko) | 2011-01-13 | 2015-09-07 | (주)바이오팜솔루션즈 | 페닐 카바메이트 유도체의 제조방법 |
US8901066B2 (en) | 2011-06-15 | 2014-12-02 | Basf Se | Branched polyesters with sulfonate groups |
ES2555872T3 (es) | 2011-06-15 | 2016-01-11 | Basf Se | Poliésteres ramificados con grupos sulfonato |
CN104136415B (zh) | 2011-12-27 | 2016-09-07 | 比皮艾思药物研发有限公司 | 用于预防或治疗中风的苯基氨基甲酸酯化合物 |
CN109939092B (zh) | 2013-03-12 | 2022-03-22 | 比皮艾思药物研发有限公司 | 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物 |
WO2014142550A1 (en) * | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same |
WO2018107060A1 (en) * | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CN110143935B (zh) * | 2019-06-03 | 2022-09-30 | 华侨大学 | 一种2,5-二取代呋喃衍生物的制备方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0219756B1 (de) | 1985-10-09 | 1994-01-05 | Shell Internationale Researchmaatschappij B.V. | Neue Acrylsäureamide |
DE3541716A1 (de) | 1985-11-26 | 1987-05-27 | Celamerck Gmbh & Co Kg | Neue acrylsaeureamide |
JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
WO1991012237A1 (fr) | 1990-02-08 | 1991-08-22 | Eisai Co., Ltd. | Derive de sulfonamide de benzene |
JPH05194517A (ja) | 1992-01-16 | 1993-08-03 | Tanabe Seiyaku Co Ltd | 6−メルカプトプリン誘導体及びその製法 |
AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
AU3577995A (en) | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
JPH08283219A (ja) | 1995-04-07 | 1996-10-29 | Eisai Co Ltd | アラルキルアミノアルキルアミド誘導体 |
TR199802282T2 (xx) | 1996-05-10 | 1999-03-22 | Icos Corporation | Karbolin t�revleri. |
CA2260860A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
JP2001508767A (ja) | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | 5―ht拮抗作用を有するインドール―ウレア誘導体 |
CN1251098A (zh) | 1997-03-31 | 2000-04-19 | 武田药品工业株式会社 | 吡咯化合物,其制备及其用途 |
JP3108997B2 (ja) | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
NZ505515A (en) * | 1997-12-31 | 2003-03-28 | Univ Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US6235728B1 (en) * | 1999-02-19 | 2001-05-22 | Bristol-Myers Squibb Company | Water-soluble prodrugs of azole compounds |
KR20020006626A (ko) | 1999-02-26 | 2002-01-23 | 폴락 돈나 엘. | 신규한 술폰아미드 화합물 및 그의 용도 |
AU2899400A (en) * | 1999-03-04 | 2000-09-21 | Nortran Pharmaceuticals Inc. | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics |
EP1264820A4 (en) | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
US20010051642A1 (en) * | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
CA2405170A1 (en) | 2000-04-24 | 2001-11-01 | Merck Frosst Canada & Co. | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
EP1349839B8 (en) * | 2000-12-04 | 2005-06-22 | F. Hoffmann-La Roche Ag | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
DK1465861T3 (da) * | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
JP2003206280A (ja) | 2001-12-28 | 2003-07-22 | Takeda Chem Ind Ltd | ビアリール化合物およびその用途 |
DE10211101A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Katalysatoren und Verfahren zur Herstellung von Aminen |
GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
US7053088B2 (en) * | 2002-05-22 | 2006-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
PT1511710E (pt) | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
OA12881A (en) | 2002-07-12 | 2006-09-15 | Aventis Pharma Gmbh | Heterocyclially substituted benzoylureas, method for their production and their use as medicaments. |
US6900354B2 (en) | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
EP1594847A2 (en) * | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
CN102584813B (zh) * | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
EP1701959A1 (en) | 2003-12-22 | 2006-09-20 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
EP1730118A1 (en) * | 2004-02-12 | 2006-12-13 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
BRPI0511504A (pt) | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
KR20070083781A (ko) * | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
JPWO2007058304A1 (ja) * | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
CA2628047A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamide derivative |
TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
WO2007060810A1 (ja) * | 2005-11-24 | 2007-05-31 | Eisai R & D Management Co., Ltd. | モルホリンタイプ・シンナミド化合物 |
CA2643796A1 (en) | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivatives |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
AR062095A1 (es) | 2006-07-28 | 2008-10-15 | Eisai R&D Man Co Ltd | Profarmaco de compuesto cinamida |
EP2117311A4 (en) | 2007-02-08 | 2011-05-11 | Merck Sharp & Dohme | THERAPEUTICS |
RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
CN101675045B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 作为β-淀粉样蛋白调节剂的杂芳基苯胺 |
WO2008156580A1 (en) | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
CA2695543A1 (en) | 2007-08-06 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
-
2007
- 2007-07-25 AR ARP070103296A patent/AR062095A1/es unknown
- 2007-07-25 SA SA7280403A patent/SA07280403B1/ar unknown
- 2007-07-25 US US11/878,556 patent/US7737141B2/en not_active Expired - Fee Related
- 2007-07-26 EP EP07791337A patent/EP2048143A4/en not_active Withdrawn
- 2007-07-26 JP JP2008526796A patent/JPWO2008013213A1/ja not_active Abandoned
- 2007-07-26 MY MYPI20090056A patent/MY144971A/en unknown
- 2007-07-26 MX MX2008015504A patent/MX2008015504A/es not_active Application Discontinuation
- 2007-07-26 EA EA200970172A patent/EA200970172A1/ru unknown
- 2007-07-26 GE GEAP200711078A patent/GEP20115176B/en unknown
- 2007-07-26 NZ NZ574102A patent/NZ574102A/en not_active IP Right Cessation
- 2007-07-26 AU AU2007277729A patent/AU2007277729A1/en not_active Abandoned
- 2007-07-26 PE PE2007000966A patent/PE20080281A1/es not_active Application Discontinuation
- 2007-07-26 WO PCT/JP2007/064637 patent/WO2008013213A1/ja active Application Filing
- 2007-07-26 KR KR1020097004007A patent/KR20090033910A/ko not_active Application Discontinuation
- 2007-07-26 TW TW096127264A patent/TW200821319A/zh unknown
- 2007-07-26 CA CA002658037A patent/CA2658037A1/en not_active Abandoned
-
2008
- 2008-12-11 CR CR10499A patent/CR10499A/es not_active Application Discontinuation
-
2009
- 2009-01-05 IL IL196351A patent/IL196351A0/en unknown
- 2009-01-06 CO CO09000699A patent/CO6150153A2/es unknown
- 2009-01-23 TN TN2009000024A patent/TN2009000024A1/fr unknown
- 2009-01-26 HN HN2009000157A patent/HN2009000157A/es unknown
- 2009-01-27 EC EC2009009091A patent/ECSP099091A/es unknown
- 2009-01-28 SV SV2009003157A patent/SV2009003157A/es unknown
- 2009-02-03 NO NO20090541A patent/NO20090541L/no not_active Application Discontinuation
- 2009-02-11 MA MA31628A patent/MA30636B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007277729A1 (en) | 2008-01-31 |
CA2658037A1 (en) | 2008-01-31 |
EA200970172A1 (ru) | 2009-08-28 |
CR10499A (es) | 2009-03-20 |
EP2048143A4 (en) | 2010-11-03 |
NZ574102A (en) | 2010-10-29 |
EP2048143A1 (en) | 2009-04-15 |
MY144971A (en) | 2011-11-30 |
HN2009000157A (es) | 2011-01-24 |
IL196351A0 (en) | 2009-09-22 |
NO20090541L (no) | 2009-02-03 |
JPWO2008013213A1 (ja) | 2009-12-17 |
KR20090033910A (ko) | 2009-04-06 |
US20090048213A1 (en) | 2009-02-19 |
AR062095A1 (es) | 2008-10-15 |
US7737141B2 (en) | 2010-06-15 |
PE20080281A1 (es) | 2008-05-05 |
MA30636B1 (fr) | 2009-08-03 |
SV2009003157A (es) | 2010-01-12 |
WO2008013213A1 (fr) | 2008-01-31 |
GEP20115176B (en) | 2011-03-10 |
TW200821319A (en) | 2008-05-16 |
SA07280403B1 (ar) | 2010-12-01 |
ECSP099091A (es) | 2009-02-27 |
MX2008015504A (es) | 2008-12-18 |
TN2009000024A1 (en) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150153A2 (es) | Farmaco de compuesto de cinamida | |
ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
MY148482A (en) | Heterocyclic compound and pharmaceutical composition thereof | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR070993A1 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como | |
EA201201052A1 (ru) | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk | |
AR083676A1 (es) | Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen | |
CO6321230A2 (es) | Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga | |
PE20121087A1 (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos | |
CO6300864A2 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
NO20073325L (no) | Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
BR112015022488A2 (pt) | triazolopiridinas substituídas e métodos de uso das mesmas | |
CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ES2308299T3 (es) | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
TW200800962A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
NI200900181A (es) | Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos. | |
AR050153A1 (es) | Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos | |
CO6362013A2 (es) | Derivados de rifamicina |